Actionable news
All posts from Actionable news
Actionable news in ACHN: Achillion Pharmaceuticals, Inc.,

Achillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside

Achillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside - Achillion Pharmaceuticals, Inc. NASDAQ:ACHN

Chardan Capital’s Madhu Kumar believes Achillion Pharmaceuticals, Inc. ACHN 1.39% is faced with several challenges, including lack of clinical data and presence of “competitive barriers” for targeted indications.

Kumar initiated coverage of the company with a Sell rating and price target of $4.

Lack Of Clinical Data

“Achillion is a clinical-stage biotechnology company focused on small molecule drugs for the complement and hepatitis C virus (HCV) therapy spaces, with clinical readouts expected in paroxysmal nocturnal hemoglobinuria (PNH) by end-2016 and in HCV in 3Q16,” the analyst mentioned.

Among the challenges facing Achillion Pharma is the fact that, while oral dosing of ACH4471 is favorable, there is absence of clinical data, which lowers the projected market share for the product in complement C5-mediated diseases (CMD).

Related Link: Valeant Responds To Former CEO's Stock Transactions: Not A Reflection Of Our Ongoing Viability

In addition, the projections for C3 glomerulopathy (C3G), “while a unique opportunity for ACH-4471, are tempered by competition and lack of data,” Kumar noted.

The analyst stated that ACH-4471 was also in development for C3G, an orphan complement C3-mediated disease of progressive kidney failure.

Other Challenges

Kumar believes C3G represents a “potentially unique market opportunity,” with 2030 risk adjusted sales estimated at $1.46 billion. However, the indication only contributes an NPV of $0.48 per share due to the long horizon for it to start generating revenue.

On the other hand, Odalasvir is also not expected to meaningfully drive revenues in the HCV therapy space. Odalasvir is an NS5A polymerase inhibitor, which is in Phase IIa combination trials for HCV therapy.

Did you like this article? Could it have been improved? Please email to let us know!

Jul 2016Chardan CapitalInitiates Coverage onSell
Jul 2016JMP SecuritiesUpgradesMarket PerformMarket Outperform
May 2016Leerink SwannMaintainsMarket Perform

© 2016 Benzinga does not provide investment advice. All rights reserved.